Analysts Anticipate Kezar Life Sciences Inc (NASDAQ:KZR) Will Post Earnings of -$0.53 Per Share

Share on StockTwits

Equities analysts expect Kezar Life Sciences Inc (NASDAQ:KZR) to announce earnings per share (EPS) of ($0.53) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kezar Life Sciences’ earnings. The lowest EPS estimate is ($0.58) and the highest is ($0.49). Kezar Life Sciences reported earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year-over-year growth rate of 76.7%. The company is expected to announce its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Kezar Life Sciences will report full-year earnings of ($1.98) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.87). For the next fiscal year, analysts expect that the company will post earnings of ($2.38) per share, with EPS estimates ranging from ($2.75) to ($2.15). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.02.

Several equities research analysts recently weighed in on the company. ValuEngine upgraded Kezar Life Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen restated a “buy” rating on shares of Kezar Life Sciences in a research report on Thursday, August 8th. HC Wainwright assumed coverage on Kezar Life Sciences in a research report on Monday, July 29th. They set a “buy” rating and a $15.00 price target on the stock. Finally, Zacks Investment Research lowered Kezar Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, July 10th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $17.50.

A number of large investors have recently made changes to their positions in KZR. BNP Paribas Arbitrage SA raised its stake in Kezar Life Sciences by 131,900.0% during the first quarter. BNP Paribas Arbitrage SA now owns 2,640 shares of the company’s stock valued at $47,000 after buying an additional 2,638 shares during the last quarter. Rhumbline Advisers bought a new position in Kezar Life Sciences in the first quarter worth approximately $245,000. Spark Investment Management LLC grew its stake in Kezar Life Sciences by 125.3% in the first quarter. Spark Investment Management LLC now owns 21,200 shares of the company’s stock worth $376,000 after purchasing an additional 11,790 shares in the last quarter. Marshall Wace LLP bought a new position in Kezar Life Sciences in the first quarter worth approximately $704,000. Finally, MetLife Investment Advisors LLC bought a new position in Kezar Life Sciences in the first quarter worth approximately $123,000. Institutional investors and hedge funds own 52.27% of the company’s stock.

Shares of NASDAQ KZR traded down $0.13 during mid-day trading on Thursday, hitting $3.49. 52,637 shares of the stock traded hands, compared to its average volume of 107,599. The company has a debt-to-equity ratio of 0.06, a quick ratio of 20.32 and a current ratio of 20.32. Kezar Life Sciences has a 52 week low of $2.82 and a 52 week high of $36.33. The company has a market cap of $67.09 million, a price-to-earnings ratio of -1.54 and a beta of 0.85. The stock has a fifty day moving average price of $4.22 and a 200-day moving average price of $11.83.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Read More: What is the Book Value of a Share?

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.